Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0BT4P
|
|||
Former ID |
DIB014605
|
|||
Drug Name |
TDI-0060
|
|||
Indication | Motor neurone disease [ICD-11: 8B60; ICD-10: G12.2; ICD-9: 335.2] | Investigative | [1] | |
Company |
ALS Therapy Development Foundation Inc
|
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Superoxide dismutase Cu-Zn (SOD Cu-Zn) | Target Info | Modulator | [1] |
BioCyc | Reactive oxygen species degradation | |||
KEGG Pathway | Peroxisome | |||
Amyotrophic lateral sclerosis (ALS) | ||||
Huntington's disease | ||||
Prion diseases | ||||
NetPath Pathway | TCR Signaling Pathway | |||
Pathwhiz Pathway | Degradation of Superoxides | |||
Pathway Interaction Database | Validated nuclear estrogen receptor alpha network | |||
FOXA1 transcription factor network | ||||
Reactome | Platelet degranulation | |||
Detoxification of Reactive Oxygen Species | ||||
WikiPathways | Oxidative Stress | |||
Copper homeostasis | ||||
Detoxification of Reactive Oxygen Species | ||||
Nifedipine Activity | ||||
Amyotrophic lateral sclerosis (ALS) | ||||
Dopamine metabolism | ||||
AGE/RAGE pathway | ||||
Folate Metabolism | ||||
Vitamin B12 Metabolism | ||||
Selenium Micronutrient Network |
References | Top | |||
---|---|---|---|---|
REF 1 | Copper binding by tetrathiomolybdate attenuates angiogenesis and tumor cell proliferation through the inhibition of superoxide dismutase 1. Clin Cancer Res. 2006 Aug 15;12(16):4974-82. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.